Eli Lilly said on Thursday its experimental weight-loss pill met most criteria for the U.S. Food and Drug Administration's ...

Eli Lilly LLY reported 54% revenue growth in the third quarter as its diabetes and obesity drug tirzepatide ...

Eli Lilly remains a top GARP opportunity, with Q3 results reinforcing its robust business growth and dominance in incretin ...

Record performance of its GLP-1 drugs sent shares in Eli Lilly soaring almost 4% after its earnings call on Thursday.

Eli Lilly shares rise as Q3 revenue jumps 54% to $17.6 billion, earnings top estimates, and analysts lift price targets on ...

S &P 500 giants Eli Lilly LLY and JPMorgan Chase JPM are stocks to watch this coming week. So is Interactive Brokers IBKR, ...

Eli Lilly (LLY) delivered standout results, with earnings climbing at a 20% annual pace over the past five years and surging 120% in the last year alone. Net profit margins rose to 31% versus 20.5% a ...

The market for obesity and diabetes treatments remains scorching hot, funneling billions in sales to Eli Lilly and fueling a bidding war over another drugmaker.

Before being discontinued, the P2X7 receptor blocker had cleared a master protocol study in chronic pain, though Eli Lilly ...

Lilly’s quarterly results Thursday, combined with Novo Nordisk’s unsolicited offer for a startup, confirm the $72 billion ...

Health-care companies rose amid earnings optimism. Eli Lilly added to gains, amid a sense that the maker of Mounjaro and Zepbound is pulling away from its competition in the obesity-drug boom. Shares ...

The AI boom is elevating the stock market to record highs, but some experts fear it's a bubble ready to burst. Does ChatGPT agree? The post I asked ChatGPT if an AI bubble will trigger the next stock ...